Moberg Pharma completes tap issue of SEK 85m


STOCKHOLM, June 30, 2016. Moberg Pharma AB (OMX: MOB) has completed a tap issue
of SEK 85 million to its outstanding bond loan (ISIN: SE0007953989). The
proceeds will be used as part financing of the acquisition of New Skin®, Fiber
Choice® and PediaCare® and for general corporate purposes.
The tap issue was made at a price of 100.50% of the nominal amount, indicating
an interest rate of Stibor 3m + 5.88%. After the tap issue, the total
outstanding amount of the Company’s bond loan amounts to SEK 385 million under a
framework amount of SEK 600 million. The bond loan is listed on Nasdaq Stockholm
and the Company will apply for listing of the new bonds on Nasdaq Stockholm. The
settlement of the tap issue will occur on July 5, 2016.

“We are pleased with the significant interest from Swedish and other Nordic
investors. Our maintained activity in the corporate bond market strengthens our
capacity to raise non-dilutive financing and we are very pleased to have been
able to issue these subsequent bonds at a premium to the nominal amount, despite
recent market turbulence”, said Peter Wolpert, CEO of Moberg Pharma AB.

Carnegie Investment Bank and Swedbank have acted as financial advisors and
Gernandt & Danielsson as legal advisor in conjunction with the tap issue.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 3.30 p.m. (CET) on June 30, 2016.
For additional information contact:
Peter Wolpert, CEO, Phone: +46 (0)70 - 735 7135, E-mail:
peter.wolpert@mobergpharma.se
Anna Ljung, CFO, Phone: +46 (0)70 - 766 60 30, E-mail:
anna.ljung@mobergpharma.se
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
OTC sales operations in the U.S. and a distributor network in more than 40
countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal
Nail®, Balmex® and Domeboro®. Kerasal Nail® (Emtrix® or Nalox™ in certain
markets) is a leading OTC treatment of nail disorders in the U.S., Canada and
several EU markets and is currently being launched in Southeast Asia. The
company is growing organically as well as through acquisitions. Internal
development programs focuses on innovative drug delivery of proven compounds and
include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain
management in oral mucositis). Moberg Pharma has offices in Stockholm and New
Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ
OMX Nordic Exchange Stockholm (OMX: MOB).

Attachments

06309483.pdf